Disodium cromoglycate inhibits capsaicin-induced eosinophil infiltration of conjunctiva independent of mast cells.
OBJECTIVE
To investigate whether disodium cromoglycate (DSCG) inhibits capsaicin-induced eosinophil infiltration of the conjunctiva independent of mast cells.


METHODS
We administered 5 microl of capsaicin solution (10(-5) M) into the conjunctival sacs of mast cell-deficient W/W(v) mice (12 animals) and wild-type mice (12 animals). As controls, the eyes of 12 wild-type and 12 W/W(v) mice were treated with phosphate-buffered saline. Following treatment, the eyelids and eyeballs were removed en bloc at 3, 9, or 24 h, and were histologically examined. The number of infiltrated eosinophils and the expression of vascular cell adhesion molecule-l (VCAM-1) in the conjunctiva were quantified by the staining method of Hansel and immunohistochemical analysis. We also investigated whether treatment by depletion of neuropeptides or by DSCG administration could suppress the capsaicin-induced eosinophil infiltration of the conjunctiva.


RESULTS
In both W/W(v) and wild-type mice, eosinophil infiltration of conjunctival tissues was observed 3 h after capsaicin administration. In both strains of mice, the number of infiltrated eosinophils increased over time, with VCAM-1 expression on vascular endothelial cells peaking at 9 h after treatment, and decreasing gradually within 24 h after treatment. In both the neuropeptide-depleted and the DSCG-treated groups, eosinophil infiltration and VCAM-1 expression were suppressed in comparison with the nontreated group.


CONCLUSIONS
DSCG can directly inhibit neuropeptide-induced eosinophil infiltration of the conjunctiva independent of mast cells.
Ebihara
Nobuyuki
N
Department of Ophthalmology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan. ebihara@med.juntendo.ac.jp
Nishikawa
Motoaki
M
Murakami
Akira
A
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D002211:Capsaicin / Q000633:toxicity; D003228:Conjunctiva / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism; D003229:Conjunctival Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000378:metabolism; D004802:Eosinophilia / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D005143:Eyelids / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D008407:Mast Cells / Q000473:pathology*; D051379:Mice; D019010:Vascular Cell Adhesion Molecule-1 / Q000096:biosynthesis
D018927:Anti-Asthmatic Agents; D019010:Vascular Cell Adhesion Molecule-1; D004205:Cromolyn Sodium; D002211:Capsaicin